We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Dolomite Offers Dedicated Microfluidics Platform for Drug Encapsulation
Product News

Dolomite Offers Dedicated Microfluidics Platform for Drug Encapsulation

Dolomite Offers Dedicated Microfluidics Platform for Drug Encapsulation
Product News

Dolomite Offers Dedicated Microfluidics Platform for Drug Encapsulation

Drug Encapsulation System

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Dolomite Offers Dedicated Microfluidics Platform for Drug Encapsulation"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Dolomite Microfluidics is simplifying research into drug encapsulation by offering a complete automated system for polymer micro- and nanoparticle generation. The company’s Drug Encapsulation System provides scientists with a quick, simple and scalable way of encapsulating drug samples, without the need for extensive microfluidics knowhow.

The Drug Encapsulation System has been developed specifically to meet the demands of the drug development sector. It draws on Dolomite’s extensive microfluidics expertise to create a straightforward and flexible solution that offers ‘plug and play’ encapsulation of drugs into biodegradable polymeric particles (e.g. PLGA). The exceptional process control offered by this system allows reliable and reproducible generation of polymer particles with a narrow size distribution, and enables the user to ‘tune’ particle size from 50 nm to 100 μm to suit their application. This approach ensures high product purity and uniform API distribution, with almost 100 % encapsulation efficiency, simplifying optimization and validation studies. Once these studies are complete, the process can be readily scaled up using Dolomite’s Telos® High Throughput Droplet System. Backed by the company’s in-depth knowledge of the drug development market, these technologies put microfluidics-based drug encapsulation within reach for virtually any laboratory.

Mark Gilligan, CEO of Dolomite, commented: “For over 15 years, we have been developing microfluidic technologies to provide reproducible particle synthesis, efficient API distribution and easy scale-up – all critical considerations for drug delivery applications. With Dolomite technology, microencapsulation has never been easier.”
Advertisement